Nureca Ltd

Nureca Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 August 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Surging past its previous peaks, Nureca Ltd touched a fresh 52-week high of Rs 348.75 on 31 Jul 2026, marking a significant milestone in its price momentum. This rally has been underpinned by a confluence of technical indicators aligning favourably, even as the broader market showed modest gains.

Nureca Ltd, a micro-cap player in the Healthcare Services sector, has seen a notable shift in its valuation parameters, moving from a risky to an expensive classification. Despite a recent surge in share price, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios raise questions about its price attractiveness relative to historical levels and peer benchmarks.

Nureca Ltd., a micro-cap healthcare services company, reported a dramatic turnaround in Q1 FY27 with net profit surging 279.01% year-on-year to ₹3.07 crores, driven by robust revenue growth and improved operational efficiency. The ₹301.81 crore market capitalisation company witnessed its stock rally 8.30% to ₹316.30 following the results announcement, though concerns about heavy reliance on other income and elevated valuations continue to cloud the investment outlook.

Nureca Ltd, a micro-cap player in the healthcare services sector, has seen its investment rating upgraded from Strong Sell to Sell as of 21 July 2026. This change reflects a nuanced shift in the company’s technical outlook amid persistent fundamental challenges. While the stock has demonstrated notable short-term momentum and positive quarterly financial results, long-term concerns remain over profitability and valuation metrics.

Nureca Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

At Rs 291.46, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nureca Ltd locked at its upper circuit of 18.69% on 14 Jul 2026, with buyers queuing and no sellers willing to part with shares.

Nureca Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 04 July 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Nureca Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 23 June 2026, providing investors with the latest insights into its performance and outlook.

Nureca Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 June 2026, providing investors with the latest insights into the stock’s fundamentals, valuation, financial trend, and technical outlook.

Nureca Ltd, a micro-cap player in the healthcare services sector, has seen its valuation parameters deteriorate significantly, with its price-to-earnings (P/E) ratio soaring to 109.5 and price-to-book value (P/BV) hovering at 1.15. This shift from an expensive to a risky valuation grade coincides with a steep 14.85% drop in its share price on 2 June 2026, signalling growing investor concerns amid underwhelming financial performance and challenging market conditions.

Nureca Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 May 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Nureca Ltd., a micro-cap home healthcare and wellness products company with a market capitalisation of ₹268.00 crores, reported a concerning fourth quarter for FY26, posting a net loss of ₹6.09 crores compared to a profit of ₹3.73 crores in the previous quarter—a dramatic reversal that has raised red flags amongst investors. The stock, trading at ₹280.90 as of May 29, 2026, remains under pressure despite a modest 1.78% gain in the most recent trading session, reflecting broader concerns about the company's operational sustainability and profitability trajectory.

Nureca Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 20 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Nureca Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Apr 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Nureca Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating upgraded from Strong Sell to Sell as of 27 Apr 2026. This change reflects a nuanced shift in the company’s technical outlook despite persistent challenges in its long-term fundamentals and valuation metrics. The upgrade is primarily driven by improvements in technical indicators, while financial trends and quality scores remain mixed, prompting a cautious stance among investors.